Subcutaneous semaglutide 2·4 mg taken once per week is a glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of obesity on the basis of the
The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are
In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2